Macro Biologics

Macro Biologics is a private, preclinical-stage biotech leveraging a proprietary platform to create synthetic biological polymers with applications in therapeutics, medical devices, and environmentally safe biomaterials. The company's lead programs are the Amicidins, a novel class of products designed to prevent life-threatening infections in surgical and traumatic wounds, with significant backing from U.S. Department of Defense and global antibiotic resistance initiatives like CARB-X. While currently pre-revenue, the company has secured non-dilutive grant funding to advance its pipeline, targeting a massive unmet need in surgical site infections and antimicrobial resistance.

Proprietary platform for designing and producing synthetic biological polymers ('macro biologics') that combine structural barrier properties with active biological functions, such as antimicrobial activity.

Competes in the crowded surgical infection prevention space against antiseptics (e.g., chlorhexidine), antibiotic-coated devices, and advanced dressings. Its differentiation lies in a novel, dual-function biologic barrier approach, but it must prove clinical superiority and cost-effectiveness against entrenched standards of care.